Levocarnitine Injection USP is a sterile, preservative-free intravenous formulation of levocarnitine, a naturally occurring compound that plays a crucial role in the transport of long-chain fatty acids into mitochondria for energy production. This injectable form is primarily used to treat and prevent carnitine deficiency in specific patient populations
Indications
1.Inborn Errors of Metabolism: Levocarnitine Injection is indicated for the acute and chronic treatment of patients with inborn errors of metabolism that result in secondary carnitine deficiency.
2.End-Stage Renal Disease (ESRD): It is also used for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis.
Dosage and Administration
1.Metabolic Disorders: The recommended dose is 50 mg/kg given as a slow 2 to 3-minute bolus injection or by infusion. A loading dose may be administered in patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. Subsequent daily doses are typically in the range of 50 mg/kg, with the highest dose administered being 300 mg/kg.
2.Monitoring: Plasma carnitine concentrations should be obtained prior to beginning therapy and monitored weekly and monthly. The plasma free carnitine concentration should be between 35 and 60 μmol/L.
Side Effects:
1.Nausea
2.vomiting
3.Headache
4.Muscle pain
